Exenatide Once Weekly: A Review of Pharmacology and Treatment Considerations in Type 2 Diabetes

详细信息    查看全文

• 作者：Stephen Brunton ; MD¹ ; ^{sbrunton@pceconsortium.org" class="auth_mail" title="E-mail the corresponding author} ; Jaime A. Davidson ; MD²
• 关键词：delayed-action preparations ; exenatide ; pharmacology ; type 2 diabetes
• 刊名：Clinical Therapeutics
• 出版年：2016
• 出版时间：March 2016
• 年：2016
• 卷：38
• 期：3
• 页码：582-594
• 全文大小：374 K

文摘

The pathophysiology of type 2 diabetes mellitus is complex and involves multiple organs and hormones, suggesting that successful treatment may require therapies that target multiple mechanisms. Exenatide, a glucagon-like peptide 1 receptor agonist, has a multifaceted mechanism of action involving pancreatic α and β cells, hepatic glucose production, gastric motility, and satiety. Exenatide once weekly (a twice-daily formulation is also available) utilizes continuous release from biodegradable microspheres. This review discusses relevant efficacy and tolerability outcomes with exenatide once weekly in the context of its pharmacology.

Methods

The medical literature was searched to identify relevant data on the pharmacology and clinical effects of exenatide once weekly.

Findings

Exenatide once weekly, like the twice-daily formulation, has been shown to improve glycemic parameters, promote weight loss, result in beneficial changes in cardiovascular risk factors, and is well-tolerated.

Implications

The characteristics of exenatide once weekly make it a treatment option for patients with type 2 diabetes.